VEXAS综合征中克隆性造血的表现谱
该研究回顾性筛查80例VEXAS综合征患者外周血克隆性造血,其中77例分析临床结局。UBA1突变最常见于热点p.M41(中位VAF 75%),60%患者合并典型克隆性造血突变(主要为DNMT3A和TET2),全组10年总生存率为60%。输血依赖性贫血、中度血小板减少和典型克隆性造血突变均与不良结局相关。
要点
- VEXAS患者中60%合并典型克隆性造血突变,主要为DNMT3A和TET2,与炎症或血液学表现无关。
- UBA1突变是显性克隆,克隆演化呈现两种主要模式。
- 输血依赖性贫血、中度血小板减少和典型克隆性造血突变与不良结局相关。
核心结论
- VEXAS中UBA1突变细胞是系统性炎症和骨髓衰竭的主要原因,VEXAS是与之相关的新的分子定义体细胞实体,VEXAS相关MDS在表现和临床病程上不同于经典MDS。
研究设计与样本
- 回顾性筛查80例VEXAS患者外周血克隆性造血,其中77例分析临床结局,并采用前瞻性单细胞蛋白质基因组测序(scDNA)。
主要发现
- UBA1突变最常见于热点p.M41(中位VAF 75%)。
- 典型克隆性造血突变与UBA1突变共存于60%患者,主要涉及DNMT3A和TET2,与炎症或血液学表现无关。
- 单细胞DNA测序显示UBA1突变是显性克隆,主要存在于分支克隆轨迹中。
- 克隆性造血呈现两种主要模式:模式1为典型克隆性造血先于克隆中UBA1突变选择,模式2为UBA1突变亚克隆或独立克隆。
- 外周血中DNMT3A与TET2克隆的VAF差异明显(中位VAF 25% vs 1%)。
关键数值与推荐
- UBA1突变热点p.M41中位VAF为75%。
- 典型克隆性造血突变与UBA1突变共存比例为60%。
- DNMT3A克隆中位VAF为25%,TET2克隆中位VAF为1%。
- 全部患者10年总生存率为60%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is caused by somatic mutations in UBA1 (UBA1mut) and characterized by heterogenous systemic autoinflammation and progressive hematologic manifestations, meeting criteria for myelodysplastic syndrome (MDS) and plasma cell dyscrasias. The landscape of myeloid-related gene mutations leading to typical clonal hematopoiesis (CH) in these patients is unknown. Retrospectively, we screened 80 patients with VEXAS for CH in their peripheral blood (PB) and correlated the findings with clinical outcomes in 77 of them. UBA1mut were most common at hot spot p.M41 (median variant allele frequency [VAF] = 75%). Typical CH mutations cooccurred with UBA1mut in 60% of patients, mostly in DNMT3A and TET2, and were not associated with inflammatory or hematologic manifestations. In prospective single-cell proteogenomic sequencing (scDNA), UBA1mut was the dominant clone, present mostly in branched clonal trajectories. Based on integrated bulk and scDNA analyses, clonality in VEXAS followed 2 major patterns: with either typical CH preceding UBA1mut selection in a clone (pattern 1) or occurring as an UBA1mut subclone or in independent clones (pattern 2). VAF in the PB differed markedly between DNMT3A and TET2 clones (median VAF of 25% vs 1%). DNMT3A and TET2 clones associated with hierarchies representing patterns 1 and 2, respectively. Overall survival for all patients was 60% at 10 years. Transfusion-dependent anemia, moderate thrombocytopenia, and typical CH mutations, each correlated with poor outcome. In VEXAS, UBA1mut cells are the primary cause of systemic inflammation and marrow failure, being a new molecularly defined somatic entity associated with MDS. VEXAS-associated MDS is distinct from classical MDS in its presentation and clinical course.
引用
- Gutierrez-Rodrigues F, Kusne Y, Fernandez J, et al. Spectrum of clonal hematopoiesis in VEXAS syndrome. Blood. 2023. PMID: 37084382. doi:10.1182/blood.2022018774
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。